The Business Case for Adherence: A Win for Pharma Is A Win For Patients
This article was originally published in RPM Report
Executive Summary
Low rates of patient adherence to medical therapy has been a persistent policy hurdle that has significant commercial implications for drug makers. The health reform debate taking place in Washington should include a solution to the problem-but pharma shouldn't take the lead.